Evidence map›Paper›PMID 42738412›Full record

ArticleCancers2026

The MAZ-POLD1 Signaling Axis Drives Cisplatin Resistance in Bladder Cancer by Activating DNA Damage Repair.

Biao Zhang, Hong Chang, Cheng Wang, Wei Chang, Shujun Yang, Yao Luo, Yuqiang Fu, Helin Zhang, Xuan Li, Can Li and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Biao ZhangDepartment of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730030, China.
Hong ChangDepartment of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730030, China.
Cheng WangDepartment of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730030, China.
Wei ChangDepartment of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730030, China.
Shujun YangDepartment of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730030, China.
Yao LuoDepartment of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730030, China.
Yuqiang FuDepartment of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730030, China.
Helin ZhangDepartment of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730030, China.
Xuan LiDepartment of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730030, China.
Can LiDepartment of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730030, China.
Jianzhong LuInstitute of Urology, Gansu Province Clinical Research Center for Urinary System Diseases, Lanzhou 730030, China.
Su ZhangDepartment of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730030, China.
Panfeng ShangDepartment of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730030, China.ORCID 0000-0002-9622-9664

Funding

Cuiying Science and Technology Innovation Project CY2024-MS-B10Cuiying Student Research Training Program CYXZPT2025-05Gansu Province Health Sector Planning Projects GSWSKY2025-47Hangzhou Oriental Clinical Oncology Research Center ECCO-KY-25007
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

bladder cancercisplatin resistanceDNA damage repairMAZPOLD1

Identifiers

PMID42738412
PMCPMC13564842

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.